Ansun Biopharma , which is committed to developing first-in-class innovative biopharmaceuticals for the most urgent and unmet clinical needs in the field of respiratory infections, announced the completion of a $80 million Series B round of financing. This round of financing was led by Haisong Capital, Dawan District Common Home Development Fund, Jiachen Capital, KIP and existing shareholders Yuanming Capital, Lilly Asia Fund, Jingwei China, Materia Medica Capital, and Jifeng Capital. Huaxing Capital acted as the exclusive financial advisor for this financing. Ansun Biopharma is a clinical stage biopharmaceutical company whose leading product in clinical development stage, DAS181, is a first-in-class recombinant sialidase protein that effectively removes sialic acid located on the surface of human airway epithelial cells, thereby preventing the virus from entering the host. Cells that block viral infections. As a host targeted therapy, DAS181 is expected to treat a variety of respiratory viruses that use the same infection mechanism. The US FDA has granted DAS181 Fast Track Eligibility and Breakthrough Therapy for the treatment of lower respiratory tract infections caused by parainfluenza virus (PIV) in immunodeficient patients.